Clinical and cerebral blood flow changes in catatonic patients treated with ECT

Clinical and cerebral blood flow changes in catatonic patients treated with ECT
复制标题

DOI:
10.1016/s0022-3999(00)00190-2
复制
发表时间:
2000-12-01
影响因子:
4.7
通讯作者:
Herrera, CP
Herrera, CP
中科院分区:
医学3区
文献类型:
--
作者:
Escobar, R;Rios, A;Herrera, CP

文献摘要

被引文献

相似文献

目的:确定精神分裂症或情绪障碍所致紧张症患者接受ECT前后临床表现和脑血流量(CBF)的变化。方法:对符合 DSM-IV 紧张症标准的 9 名患者进行了研究。患者接受 5 至 15 次(每周三次)ECT。使用改良罗杰斯量表(MRS)测量紧张症的严重程度。 CBF 的变化通过大脑单正电子发射计算机断层扫描 (SPECT) 进行测量,该扫描在第一次 ECT 前 1 周和最后一次 ECT 后 1 周形成 PCR。结果:5名患者的紧张症是由精神分裂症引起的,4名患者是由情绪障碍引起的。治疗前两组之间没有显着的临床和脑 SPECT 差异。 ECT 治疗前与 ECT 治疗后的比较显示,两组的紧张性症状均显着减轻。然而,患有情绪障碍的患者需要更少的 ECT 治疗,并且表现出更大的临床改善。脑SPECT显示,情绪障碍患者的顶叶、颞叶和枕叶区域的CBF显着增加,而精神分裂症患者则无显着变化。结论:这些结果支持 ECT 对治疗紧张症患者的疗效,尤其是继发于情绪障碍的患者,这似乎与 CBF 的改善相关。 (C) 2001 爱思唯尔科学公司。版权所有。
Objective: To determine changes in clinical manifestations and cerebral blood flow (CBF) before and after administration of ECT to patients with catatonia due to schizophrenia or mood disorders. Methods: A sample of nine patients who met DSM-IV criteria for catatonia was studied. Patients received between 5 and 15 sessions (thrice per week) of ECT. Severity of catatonia was measured with the Modified Rogers Scale (MRS). Changes in CBF were measured with a brain single positron emission computer tomography (SPECT) that was pcr formed 1 week before the first ECT and 1 week after the last ECT. Results: Catatonia was due to schizophrenia in five patients and mood disorders in four patients. There were no significant clinical and brain SPECT differences between these two groups before treatment. Pre- vs. post-ECT comparisons showed significant reduction of catatonic symptoms in both groups. However, patients with mood disorders needed less ECT sessions and showed greater clinical improvement. Brain SPECT showed significant increase in CBF in parietal, temporal, and occipital regions in patients with mood disorder and no significant changes in patients with schizophrenia. Conclusions: These results support the efficacy of ECT for treatment of catatonic patients, especially secondary to mood disorders, which seem to be correlated with improvements in CBF. (C) 2001 Elsevier Science inc. All rights reserved.